Ovarian cancer screening approach may be flawed

	Tweet

Annual ultrasound examination plus a blood tests to detect CA-125, a biologic tumor marker, may be adequate to detect early-stage Ovarian cancer in women at increased genetic risk, according to UK researchers.

The two cancer screening methods are “ineffective in detecting tumors at a sufficiently early stage to influence prognosis,” Dr. Diane Sterling of Western General Hospital, Edinburgh and colleagues report in the Journal of Clinical Oncology.

The team came to this conclusion after examining data for 1,110 women with an increased risk of Ovarian cancer who were screened between 1991 and 2004. Of these subjects, 553 had a 4-percent to 10-percent lifetime Ovarian cancer risk and were deemed to be at moderate risk. The remaining 557 had a greater than 10-percent lifetime risk and were classified as high risk.

Overall, 12 invasive and one borderline ovarian malignancy developed in the group. Ten of these tumors were detected at screening.

Of the other three, one was found when the patient underwent surgical removal of the ovaries two months after normal screening results. The other two women developed symptoms within 12 months after normal screening results. Twenty-nine women underwent diagnostic surgery, but were not found to have Ovarian cancer.

Based on the findings, the researchers conclude that “the performance of ultrasound does not satisfy the World Health Organization screening standards.”

In addition, this combination screening approach “has a particularly high false-positive rate in premenopausal women, leading to unnecessary surgical intervention,” the researchers note.

However, in an accompanying editorial, Dr. Ian Jacobs of University College, London finds the study methodologically flawed. The researchers’ results may be correct, he points out, “but it is not possible to reach this conclusion from the data they have presented.”

In light of this and other studies in the medical literature, he stresses the “need for well-designed, rigorously conducted and properly funded...trials of Ovarian cancer screening.”

SOURCE: Journal of Clinical Oncology, August 20, 2005.

RELATED STORIES:
Women often opt to surgically remove their breasts, ovaries to reduce cancer risk   More study needed on vitamin D-ovarian cancer link   Study unmasks how ovarian tumors evade immune system   OHSU Primate Center’s Ovarian Cancer Finding May be a “Win-Win” for At-Risk Women Who Wish to Have a Family   Analgesic drugs don’t reduce ovarian cancer risk   Experimental Drug Boosts Survival Time For Recurrent Ovarian Cancer   Ovarian cancer screening popular despite guidelines   Optimistic women with ovarian cancer fare better   St. John’s wort and polymeric nanoparticles to treat ovarian tumors using light   Processed meat linked to higher ovarian cancer risk   Soy may lessen risk of endometrial, ovarian cancers   DNA Repair Genes May Predict Ovarian Cancer Survival   Symptom screening plus a simple blood test improves early detection of ovarian cancer   New Antibody Offers Hope for Treating Ovarian, Breast Cancer   Low dose naltrexone (LDN): Harnessing the body’s own chemistry to treat human ovarian cancer   Ovarian cancer patients survive longer with BRCA2 mutated in tumors   Avastin helps in ovarian cancer but effects fade   Ginkgo may ward off ovarian cancer   Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward   2 studies find new genetic links to ovarian cancer risk   Ovarian Cancer May Mimic Fallopian Tube Formation   TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]